• Explore /
  • Poster
  • / Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.

Abstract Poster

Authors

Arjun Mittra

Arjun Mittra

Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

Arjun Mittra , Geraldine Helen O'Sullivan Coyne , Khanh Tu Do , Sarina Anne Piha-Paul , Shivaani Kummar , Naoko Takebe , Ashley Bruns , Lamin Juwara , Lawrence Rubinstein , Murielle Hogu , Robert J. Kinders , Ralph E. Parchment , Brandon Miller , Deborah Wilsker , M. Cecilia Monge B. , Sabrina Sharmin Khan , L. Austin Doyle , James H. Doroshow , Alice P. Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Conduct of Clinical Research

Clinical Trial Registration Number

NCT02723864

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3067)

DOI

10.1200/JCO.2019.37.15_suppl.3067

Abstract #

3067

Poster Bd #

59

Abstract Disclosures

Similar Posters

First Author: Geraldine Helen O'Sullivan Coyne

First Author: Taofeek Kunle Owonikoko

First Author: Toshio Shimizu

First Author: Ecaterina Elena Dumbrava